Titlebook: New Drugs, Concepts and Results in Cancer Chemotherapy; F. M. Muggia Book 1991 Springer Science+Business Media New York 1991 cancer.chemot

Gleason-score

光滑

Michael D. Green,Peggy Alderton,Mordechai M. Sobol,Janet Gross,Franco M. Muggia,James L. Speyericht in “langwierigen” Gesprächen von der Eignung der Instrumente zu überzeugen hat — der Forschungs- und Entwicklungs-Controller kann auf das Setzen deutlicher Signale seitens der Geschäftsführung verweisen. Ferner sind Bereichs- oder Abteilungsleiter dazu angehalten, sich kritisch mit den Instrume

使坚硬

Nikhil C. Munshi,Patrick J. Loehrer,Stephen D. Williamsicht in “langwierigen” Gesprächen von der Eignung der Instrumente zu überzeugen hat — der Forschungs- und Entwicklungs-Controller kann auf das Setzen deutlicher Signale seitens der Geschäftsführung verweisen. Ferner sind Bereichs- oder Abteilungsleiter dazu angehalten, sich kritisch mit den Instrume

厚颜无耻

无辜

ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: Clinical and preclcess, selectively abrogated the toxic cardiomyopathy caused by anthracyclines without adversely affecting the antitumor response indicates that there must be different mechanisms of anthracycline action, either in different tissues and/or in malignant versus non-malignant cells.

Chagrin

Thierry Le Chevalier,Rodrigo Arriagada,Maurice Tubiana

小卒

New Drugs, Concepts and Results in Cancer Chemotherapy

情感

Modulation of the activity of cancer chemotherapeutic agents by dipyridamolepyridamole can modulate the activity of a number of chemotherapeutic agents and may have the ability to enhance their therapeutic index. We review here the cellular and biochemical mechanisms by which dipyridamole alters cancer cell sensitivity and point out potential clinical applications.

傻瓜

Folate antimetabolites inhibitory to , purine synthesiserim and that the potential of folate antimetabolites as therapeutic agents is established.Of course, the pharmaceutical promise for a new class of folate antimetabolites also continues to be high, given the central nature of the folate-dependent enzymes in processes required for any proliferative cell population.

acetylcholine

Uroprotection in patients receiving cyclophosphamide and ifosfamiden has been designing agents that are pharmacologically noncytotoxic but control or prevent toxic side effects of an administered cytotoxic agent. These protective agents allow administration of presently available agents at much higher doses.